# Effect of multiparametric MRI and ultrasound-guided biopsy for early prostate cancer detection: A prospective cohort study

## TL;DR

This study shows that using multiparametric MRI improves early detection of significant prostate cancer compared to traditional ultrasound-guided biopsy.

## Contribution

The study provides empirical evidence that mpMRI outperforms TRUS-guided biopsy in detecting clinically significant prostate cancer.

## Key findings

- mpMRI had higher sensitivity (91%) and specificity (76%) compared to TRUS biopsy (68% and 60%).
- mpMRI identified 22% more clinically significant cancers than TRUS-guided biopsy.
- mpMRI showed better positive and negative predictive values than TRUS-guided biopsy.

## Abstract

It is essential to detect clinically significant prostate cancer (csPCa) in an early and precise manner. However, there are challenges
given that the usual TRUS-guided biopsy may leave tumors undiagnosed, or only detect indolent disease. In this prospective cohort study of
200 patients, we compared the diagnostic accuracy of multiparametric MRI (mpMRI) with TRUS-guided biopsy. The study found better
sensitivity (91% vs 68%) and specificity (76% vs 60%) than TRUS biopsy, and identified 22% more clinically significant cancers than TRUS
biopsies. In addition, mpMRI showed better positive predictive value and negative predictive value than TRUS-guided biopsy; this suggests
general advantage in diagnostic accuracy and performance for mpMRI. Data shows, there is support for mpMRI having improved efficacy as a
method of detecting clinically significant prostate cancer early compared to TRUS-guided biopsy.